AR095117A1 - TRANSFORMANTE DE LEVADURA RECOMBINANTE Y PROCEDIMIENTO DE PREPARACIÓN DE FRAGMENTOS Fc DE INMUNOGLOBULINA USANDO EL MISMO - Google Patents

TRANSFORMANTE DE LEVADURA RECOMBINANTE Y PROCEDIMIENTO DE PREPARACIÓN DE FRAGMENTOS Fc DE INMUNOGLOBULINA USANDO EL MISMO

Info

Publication number
AR095117A1
AR095117A1 ARP140100336A ARP140100336A AR095117A1 AR 095117 A1 AR095117 A1 AR 095117A1 AR P140100336 A ARP140100336 A AR P140100336A AR P140100336 A ARP140100336 A AR P140100336A AR 095117 A1 AR095117 A1 AR 095117A1
Authority
AR
Argentina
Prior art keywords
immunoglobulin
fragment
transformant
same
preparation procedure
Prior art date
Application number
ARP140100336A
Other languages
English (en)
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR095117A1 publication Critical patent/AR095117A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • C12N1/16Yeasts; Culture media therefor
    • C12N1/18Baker's yeast; Brewer's yeast
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente se refiere a un transformante preparado mediante la introducción de un vector de expresión que comprende un polinucleótido que codifica un fragmento Fc de inmunoglobulina humana en levadura Pichia sp., a un procedimiento de producción de un fragmento Fc de inmunoglobulina, que comprende cultivar el transformante y recuperar el fragmento Fc de inmunoglobulina del cultivo, y a un fragmento Fc de inmunoglobulina, preparado mediante el procedimiento anterior para su uso como un vehículo farmacológico. El transformante se sugiere como una solución a los problemas asociados al uso de células de E. coli o animales como huéspedes para producir fragmentos Fc de inmunoglobulina útiles como vehículos farmacológicos, de modo que pueda encontrar diversas aplicaciones en la producción eficaz y económica de fármacos.
ARP140100336A 2013-01-31 2014-01-31 TRANSFORMANTE DE LEVADURA RECOMBINANTE Y PROCEDIMIENTO DE PREPARACIÓN DE FRAGMENTOS Fc DE INMUNOGLOBULINA USANDO EL MISMO AR095117A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020130011471A KR102073748B1 (ko) 2013-01-31 2013-01-31 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법

Publications (1)

Publication Number Publication Date
AR095117A1 true AR095117A1 (es) 2015-09-30

Family

ID=51262604

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100336A AR095117A1 (es) 2013-01-31 2014-01-31 TRANSFORMANTE DE LEVADURA RECOMBINANTE Y PROCEDIMIENTO DE PREPARACIÓN DE FRAGMENTOS Fc DE INMUNOGLOBULINA USANDO EL MISMO

Country Status (14)

Country Link
US (1) US9394546B2 (es)
EP (1) EP2951284B1 (es)
JP (1) JP6473696B2 (es)
KR (1) KR102073748B1 (es)
CN (1) CN105073977B (es)
AR (1) AR095117A1 (es)
AU (1) AU2014213134B2 (es)
CA (1) CA2899838C (es)
DK (1) DK2951284T3 (es)
ES (1) ES2865443T3 (es)
RU (1) RU2664862C2 (es)
SG (1) SG11201505800RA (es)
TW (1) TWI628279B (es)
WO (1) WO2014119956A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102073748B1 (ko) * 2013-01-31 2020-02-05 한미약품 주식회사 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법
KR101895634B1 (ko) * 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
KR20170037247A (ko) * 2015-09-25 2017-04-04 한미약품 주식회사 개시 메티오닌 잔기를 포함하는 면역글로불린 Fc 영역의 생산방법
MX2022000758A (es) * 2019-07-18 2022-02-11 Hanmi Pharm Ind Co Ltd Procedimiento novedoso para preparar un conjugado de farmaco de accion prolongada mediante la preparacion de un intermedio.
US20220273808A1 (en) * 2019-07-18 2022-09-01 Hanmi Pharm. Co., Ltd Novel method of preparing protein conjugate
BR112022023738A2 (pt) * 2020-05-22 2023-01-31 Hanmi Pharm Ind Co Ltd Formulação líquida

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504099D0 (en) 1985-02-18 1985-03-20 Wellcome Found Physiologically active substances
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
DK0835939T3 (da) 1990-06-28 2006-03-13 Sanofi Aventis Deutschland Fusionsproteiner med andele af immunglobulin, deres fremstilling og anvendelse
EP0533006A1 (en) 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
JPH11174A (ja) * 1997-06-13 1999-01-06 Asahi Breweries Ltd 酵母を用いた抗体Fab断片の製造法
CN100480266C (zh) 1998-10-16 2009-04-22 拜奥根Idec马萨诸塞公司 干扰素-β融合蛋白及用途
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2379388C (en) 1999-07-13 2012-05-29 George N. Cox, Iii Immunoglobulin fusion proteins
DE10021731B4 (de) 2000-05-04 2005-12-08 Aventis Pharma Deutschland Gmbh Cyclipostine, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung derselben
US6797493B2 (en) * 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
AU2004282984B2 (en) 2003-11-13 2011-07-14 Hanmi Science Co., Ltd. Protein complex using immunoglobulin fragment andmethod for the preparation thereof
KR20050098032A (ko) 2004-01-19 2005-10-11 타이완 오아시스 테크놀러지 컴퍼니 리미티드 백색광 led 및 상기 백색광 led로부터 발생된 광의색상을 조정하는 방법
KR100594607B1 (ko) 2004-11-03 2006-06-30 재단법인서울대학교산학협력재단 신규한 경구투여용 재조합 인간 성장호르몬 분비미생물제제 및 그 제조방법
EP1913027B1 (en) * 2005-07-28 2015-03-04 Novartis AG M-csf specific monoclonal antibody and uses thereof
MY149128A (en) * 2005-08-16 2013-07-15 Hanmi Science Co Ltd A method for the mass production of immunoglobulin fc region deleted initial methionine residues
CN1974601A (zh) 2005-11-28 2007-06-06 上海新生源医药研究有限公司 一种新型Fc融合蛋白及其生产方法
MX2009010492A (es) * 2007-03-30 2009-10-19 Abbott Lab Elementos de vector de expresion recombinante (reves) para mejorar la expresion de proteinas recombinantes en celulas huesped.
US20100255012A1 (en) * 2007-05-31 2010-10-07 Genmab A/S Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering
KR100980411B1 (ko) * 2007-10-15 2010-09-07 서울대학교산학협력단 유전자 변형 미생물의 조건적 자살을 이용한 치료 단백질의소장 전달방법
CN101748145A (zh) * 2008-12-03 2010-06-23 中国人民解放军军事医学科学院生物工程研究所 表达抗体或抗体类似物的重组酵母菌及其构建方法与应用
EP2275442A1 (en) * 2009-07-06 2011-01-19 Ludwig-Maximilians-Universität München Detection and vizualization of the cell cycle in living cells
KR102073748B1 (ko) * 2013-01-31 2020-02-05 한미약품 주식회사 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법

Also Published As

Publication number Publication date
RU2664862C2 (ru) 2018-08-23
TW201443234A (zh) 2014-11-16
CA2899838A1 (en) 2014-08-07
JP6473696B2 (ja) 2019-02-20
JP2016505277A (ja) 2016-02-25
CA2899838C (en) 2023-03-07
ES2865443T3 (es) 2021-10-15
AU2014213134B2 (en) 2020-01-23
EP2951284A1 (en) 2015-12-09
CN105073977A (zh) 2015-11-18
BR112015018288A2 (pt) 2018-08-14
TWI628279B (zh) 2018-07-01
EP2951284A4 (en) 2016-08-17
DK2951284T3 (da) 2021-04-26
WO2014119956A1 (en) 2014-08-07
KR20140098607A (ko) 2014-08-08
EP2951284B1 (en) 2021-03-31
US9394546B2 (en) 2016-07-19
AU2014213134A1 (en) 2015-08-13
SG11201505800RA (en) 2015-08-28
US20150361437A1 (en) 2015-12-17
NZ710448A (en) 2021-01-29
KR102073748B1 (ko) 2020-02-05
RU2015133452A (ru) 2017-03-07
CN105073977B (zh) 2020-11-10

Similar Documents

Publication Publication Date Title
AR095117A1 (es) TRANSFORMANTE DE LEVADURA RECOMBINANTE Y PROCEDIMIENTO DE PREPARACIÓN DE FRAGMENTOS Fc DE INMUNOGLOBULINA USANDO EL MISMO
AR103161A1 (es) Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
CO2017001561A2 (es) Anticuerpos anti tigit
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
BR112016012129A8 (pt) métodos para produção, expansão e purificação de células epiteliais do pigmento da retina, composição farmacêutica e uso das células
GT201400162A (es) Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas
BR112019000718A2 (pt) processo para a produção de geopolímero ou compósito de geopolímero
PE20151410A1 (es) Moleculas biespecificas de union a antigeno activadoras de celulas t
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
WO2015032906A3 (en) Cd70-binding peptides and method, process and use relating thereto
PE20150752A1 (es) Proteinas de fusion de interleuquina-2 y usos de las mismas
MX2015016835A (es) Metodo para reticular acido hialuronico; metodo para preparar un hidrogel inyectable; el hidrogel obtenido; el uso del hidrogel obtenido.
CL2016001592A1 (es) Anticuerpos y métodos de uso
AR088252A1 (es) Produccion de una proteina de interes mediante un promotor regulable de pichia pastoris
BR112014029252B8 (pt) Método para a construção de uma célula hospedeira fúngica recombinante, célula hospedeira fúngica recombinante, e, método de produção de um polipeptídeo de interesse
EP3148569A4 (en) Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
NZ707777A (en) Mdr e. coli specific antibody
BR112017008672A2 (pt) anticorpos de il-6 melhorados
AR110087A1 (es) Método para la preparación de células de levadura electrocompetentes, y método para la utilización de dichas células
AR090668A1 (es) Anticuerpo anti-adamts-5, derivados y usos del mismo
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
BR112016012371A2 (pt) produção microbial de aminas graxas
EA201691953A1 (ru) Белки тонопласта, функционирующие как протон/сахар-антипортеры, и их использование для повышения концентрации сахарозы в запасающем сахарозу органе растений
UY36441A (es) Supresión de arni parental de gen hunchback para el control de las plagas de hemípteros
IN2014DN07958A (es)

Legal Events

Date Code Title Description
FC Refusal